Hereditary risk of breast and ovarian cancer: BRCA1 and BRCA2

Publikation: Bidrag til bog/antologi/rapport › Bidrag til bog/antologi › Forskning › fagfællebedømt

Standard

Hereditary risk of breast and ovarian cancer : BRCA1 and BRCA2. / Sørensen, Claus Storgaard.

Encyclopedia of Cancer. Elsevier, 2018. s. 214-217.

Publikation: Bidrag til bog/antologi/rapport › Bidrag til bog/antologi › Forskning › fagfællebedømt

Harvard

Sørensen, CS 2018, Hereditary risk of breast and ovarian cancer: BRCA1 and BRCA2. i Encyclopedia of Cancer. Elsevier, s. 214-217. https://doi.org/10.1016/B978-0-12-801238-3.65227-3

APA

Sørensen, C. S. (2018). Hereditary risk of breast and ovarian cancer: BRCA1 and BRCA2. I Encyclopedia of Cancer (s. 214-217). Elsevier. https://doi.org/10.1016/B978-0-12-801238-3.65227-3

Vancouver

Sørensen CS. Hereditary risk of breast and ovarian cancer: BRCA1 and BRCA2. I Encyclopedia of Cancer. Elsevier. 2018. s. 214-217 https://doi.org/10.1016/B978-0-12-801238-3.65227-3

Author

Sørensen, Claus Storgaard. / Hereditary risk of breast and ovarian cancer : BRCA1 and BRCA2. Encyclopedia of Cancer. Elsevier, 2018. s. 214-217

Bibtex

@inbook{4a13a0682d8343e2806594abbb4d9baa,
title = "Hereditary risk of breast and ovarian cancer: BRCA1 and BRCA2",
abstract = "Germline genetic abnormalities in the tumor suppressors BRCA1 and BRCA2 predispose to hereditary breast and ovarian cancer (HBOC) in an autosomal-dominant manner. BRCA1 and BRCA2 are important for DNA repair, when mutated, chromosomal DNA accumulates further mutations that fuels tumorigenesis. Clinical genetic laboratory testing of individuals at risk identifies HBOC predisposing gene variants, which is crucial to guide between several management options for the condition. Furthermore, precise information regarding pathogenic variants supports treatment choices in the event of cancer development.",
keywords = "BRCA1, BRCA2, Breast cancer, Genetic counseling, Genetic testing, Homologous recombination DNA repair, Ovarian cancer, PALB2, PARP inhibition, Risk assessment",
author = "S{\o}rensen, {Claus Storgaard}",
year = "2018",
month = jan,
day = "1",
doi = "10.1016/B978-0-12-801238-3.65227-3",
language = "English",
pages = "214--217",
booktitle = "Encyclopedia of Cancer",
publisher = "Elsevier",
address = "Netherlands",

}

RIS

TY - CHAP

T1 - Hereditary risk of breast and ovarian cancer

T2 - BRCA1 and BRCA2

AU - Sørensen, Claus Storgaard

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Germline genetic abnormalities in the tumor suppressors BRCA1 and BRCA2 predispose to hereditary breast and ovarian cancer (HBOC) in an autosomal-dominant manner. BRCA1 and BRCA2 are important for DNA repair, when mutated, chromosomal DNA accumulates further mutations that fuels tumorigenesis. Clinical genetic laboratory testing of individuals at risk identifies HBOC predisposing gene variants, which is crucial to guide between several management options for the condition. Furthermore, precise information regarding pathogenic variants supports treatment choices in the event of cancer development.

AB - Germline genetic abnormalities in the tumor suppressors BRCA1 and BRCA2 predispose to hereditary breast and ovarian cancer (HBOC) in an autosomal-dominant manner. BRCA1 and BRCA2 are important for DNA repair, when mutated, chromosomal DNA accumulates further mutations that fuels tumorigenesis. Clinical genetic laboratory testing of individuals at risk identifies HBOC predisposing gene variants, which is crucial to guide between several management options for the condition. Furthermore, precise information regarding pathogenic variants supports treatment choices in the event of cancer development.

KW - BRCA1

KW - BRCA2

KW - Breast cancer

KW - Genetic counseling

KW - Genetic testing

KW - Homologous recombination DNA repair

KW - Ovarian cancer

KW - PALB2

KW - PARP inhibition

KW - Risk assessment

UR - http://www.scopus.com/inward/record.url?scp=85079110117&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-801238-3.65227-3

DO - 10.1016/B978-0-12-801238-3.65227-3

M3 - Book chapter

AN - SCOPUS:85079110117

SP - 214

EP - 217

BT - Encyclopedia of Cancer

PB - Elsevier

ER -

ID: 251833367